Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools Inc. (Nasdaq:LAB) has announced its management team's participation in two upcoming investor conferences in August 2024. The events are:
1. Canaccord Genuity 44th Annual Growth Conference on August 13th, where President and CEO Michael Egholm, PhD, will participate in a fireside chat at 9:00 a.m. ET.
2. UBS Genomic Medicine Summit on August 14th, where Dr. Egholm will join a panel discussion titled 'Expanding Horizons - Spatial and Beyond' at 2:00 p.m. PT.
Available presentations will be webcast live on the company's Investor Relations page. Recordings will be archived and accessible at investors.standardbio.com.
Standard BioTools Inc. (Nasdaq:LAB) ha annunciato la partecipazione del suo team di gestione a due conferenze per investitori che si terranno ad agosto 2024. Gli eventi sono:
1. 44a Conferenza Annuale sulla Crescita di Canaccord Genuity il 13 agosto, dove il Presidente e CEO Michael Egholm, PhD, parteciperà a una chiacchierata informale alle 9:00 ET.
2. Summit sulla Medicina Genomica di UBS il 14 agosto, dove il Dr. Egholm parteciperà a un panel dal titolo 'Espandere gli Orizzonti - Spaziale e oltre' alle 14:00 PT.
Le presentazioni disponibili saranno trasmesse in diretta sulla pagina delle Relazioni con gli Investitori dell'azienda. Le registrazioni saranno archiviate e accessibili su investors.standardbio.com.
Standard BioTools Inc. (Nasdaq:LAB) ha anunciado la participación de su equipo de gestión en dos conferencias para inversores que se llevarán a cabo en agosto de 2024. Los eventos son:
1. 44a Conferencia Anual de Crecimiento de Canaccord Genuity el 13 de agosto, donde el Presidente y CEO Michael Egholm, PhD, participará en una charla informal a las 9:00 a.m. ET.
2. Cumbre sobre Medicina Genómica de UBS el 14 de agosto, donde el Dr. Egholm se unirá a un panel de discusión titulado 'Ampliando Horizontes - Espacial y Más Allá' a las 2:00 p.m. PT.
Las presentaciones disponibles serán transmitidas en vivo en la página de Relaciones con Inversores de la compañía. Las grabaciones se archivarán y estarán accesibles en investors.standardbio.com.
스탠다드 바이오툴스 인크. (Nasdaq:LAB)는 2024년 8월에 열리는 두 개의 투자자 컨퍼런스에 경영진이 참여한다고 발표했습니다. 이 두 행사는 다음과 같습니다:
1. 캐나다고르드 제너리티 제44회 연례 성장 컨퍼런스가 8월 13일에 열리며, CEO 마이클 에홀름 박사가 오전 9시(동부 표준시)에서 화로 대화에 참여합니다.
2. UBS 유전체 의학 서밋가 8월 14일에 개최되며, 에홀름 박사가 '수평 확장 - 공간 및 그 이상'이라는 패널 토론에 오후 2시(태평양 표준시)에 참석합니다.
제공되는 발표 자료는 회사의 투자자 관계 페이지에서 실시간 방송됩니다. 녹화된 자료는 아카이브되어 investors.standardbio.com에서 접속할 수 있습니다.
Standard BioTools Inc. (Nasdaq:LAB) a annoncé la participation de son équipe de direction à deux conférences d'investisseurs à venir en août 2024. Les événements sont :
1. 44ème Conférence Annuelle de Croissance de Canaccord Genuity le 13 août, où le Président et CEO Michael Egholm, PhD, participera à une discussion informelle à 9h00 ET.
2. Sommet UBS sur la Médecine Génomique le 14 août, où Dr. Egholm rejoindra une table ronde intitulée 'Élargir les Horizons - Spatial et Au-delà' à 14h00 PT.
Les présentations disponibles seront diffusées en direct sur la page des Relations Investisseurs de l'entreprise. Les enregistrements seront archivés et accessibles sur investors.standardbio.com.
Standard BioTools Inc. (Nasdaq:LAB) hat die Teilnahme seines Managementteams an zwei bevorstehenden Investorenkonferenzen im August 2024 angekündigt. Die Veranstaltungen sind:
1. 44. Jahreswachstumskonferenz von Canaccord Genuity am 13. August, wo Präsident und CEO Michael Egholm, PhD, an einem informellen Gespräch um 9:00 Uhr ET teilnehmen wird.
2. UBS Genommedizin Gipfel am 14. August, wo Dr. Egholm an einer Podiumsdiskussion mit dem Titel 'Horizonte erweitern - räumlich und darüber hinaus' um 14:00 Uhr PT teilnehmen wird.
Die verfügbaren Präsentationen werden live übertragen auf der Investor Relations-Seite des Unternehmens. Aufzeichnungen werden archiviert und sind unter investors.standardbio.com zugänglich.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that its management team will participate in the following investor conferences in the month of August:
- Canaccord Genuity 44th Annual Growth Conference on August 13th, 2024
President and CEO, Michael Egholm, PhD, will participate in a fireside chat on Tuesday, August 13, 2024, at 9:00 a.m. ET - UBS Genomic Medicine Summit on August 14th, 2024
President and CEO, Michael Egholm, PhD, will participate in a panel discussion:
Expanding Horizons - Spatial and Beyond on Wednesday, August 14, 2024, at 2:00 p.m. PT
Available presentations will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms. Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact:
David Holmes
Gilmartin Group LLC
(332) 330-1031
ir@standardbio.com
FAQ
What investor conferences will Standard BioTools (LAB) participate in during August 2024?
Who will represent Standard BioTools (LAB) at these investor conferences?
What type of presentation will Standard BioTools (LAB) give at the Canaccord Genuity conference?
What panel will Standard BioTools (LAB) participate in at the UBS Genomic Medicine Summit?
Where can investors access the webcasts of Standard BioTools (LAB) presentations?
